Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNPR Monopar Therapeutics

Post-Mkt 12-11 19:44:12 EST

77.05

-1.17

-1.50%

盘后77.05

+0.000.00%

17:54 EST

High79.02	Low75.00	Vol113.01K
Open78.72	D1 Closing78.22	Amplitude5.13%
Mkt Cap514.89M	Tradable Cap379.98M	Total Shares6.68M
T/O8.72M	T/O Rate2.29%	Tradable Shares4.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MNPR","market":"US","secType":"STK","nameCN":"Monopar Therapeutics","latestPrice":77.05,"timestamp":1765486800000,"preClose":78.22,"halted":0,"volume":113008,"hourTrading":{"tag":"盘后","latestPrice":77.05,"preClose":77.05,"latestTime":"17:54 EST","volume":2511,"amount":193472.55,"timestamp":1765493643845},"delay":0,"floatShares":4931541,"shares":6682584,"eps":-2.989461,"marketStatus":"Post-Mkt","change":-1.17,"latestTime":"12-11 19:44:12 EST","open":78.72,"high":79.015,"low":75,"amount":8724055.99856,"amplitude":0.05133,"askPrice":78.58,"askSize":25,"bidPrice":75.56,"bidSize":26,"shortable":3,"etf":0,"ttmEps":-2.989461,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"listingDate":1576731600000,"exchange":"NASDAQ","adjPreClose":78.22,"preHourTrading":{"tag":"盘前","latestPrice":79.31,"preClose":78.22,"latestTime":"08:09 EST","volume":25,"amount":1982.75,"timestamp":1765458593945},"postHourTrading":{"tag":"盘后","latestPrice":77.05,"preClose":77.05,"latestTime":"17:54 EST","volume":2511,"amount":193472.55,"timestamp":1765493643845},"volumeRatio":0.679945},"requestUrl":"/m/hq/s/MNPR","defaultTab":"news","newsList":[{"id":"1182700154","title":"Stock Track | Monopar Therapeutics Soars 8.74% Following Analyst's Buy Rating and $130 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1182700154","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182700154?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:02","pubTimestamp":1763492536,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (MNPR) stock surged 8.74% during Tuesday's intraday trading session, following a bullish analyst report. The significant uptick in share price comes as investors react positively...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNPR"],"gpt_icon":0},{"id":"2584495041","title":"Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2584495041","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584495041?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:45","pubTimestamp":1763491527,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $130.00. Soumi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-monopar-therapeutics-inc-promising-alxn1840-data-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-monopar-therapeutics-inc-promising-alxn1840-data-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2583689591","title":"Monopar Therapeutics Shares Fall After Raymond James Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2583689591","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583689591?lang=en_us&edition=fundamental","pubTime":"2025-11-15 03:54","pubTimestamp":1763150091,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics  shares fell 6.8% in recent Friday trading after Raymond James downgraded the stock to outperform from strong buy and cut its price target to $123 from $142.Trading volume stood at about 200,000 shares, compared with the daily average of roughly 88,000.Price: 81.11, Change: -5.90, Percent Change: -6.78","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNPR","RJF"],"gpt_icon":0},{"id":"1121303799","title":"Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1121303799","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121303799?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:33","pubTimestamp":1763130781,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNPR"],"gpt_icon":0},{"id":"2583356570","title":"BTIG Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583356570","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583356570?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:17","pubTimestamp":1763119023,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jeet Mukherjee from BTIG reiterated a Buy rating on Monopar Therapeutics Inc, with a price target of $104.00. The c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2583512927","title":"Monopar Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512927?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:25","pubTimestamp":1763069100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 16:25 ET (21:25 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"gpt_icon":0},{"id":"2583598307","title":"Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598307","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598307?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:06","pubTimestamp":1763039201,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.45) by 7.38 percent. This is a 29.73 percent decrease over losses of $(0.37) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48831407/monopar-therapeutics-q3-eps-0-48-misses-0-45-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"gpt_icon":0},{"id":"2583459885","title":"Monopar Therapeutics reports third quarter net loss of $3.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583459885","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583459885?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:01","pubTimestamp":1763038896,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc. reported a net loss of $3.4 million, or $0.48 per share, for the third quarter of 2025, compared to a net loss of $1.3 million, or $0.37 per share, for the same period in 2024. As of September 30, 2025, the company held $143.7 million in cash, cash equivalents, and investments. Recent business developments include FDA clearance of an IND application for MNPR-101-Lu, a Phase 1 trial for advanced or metastatic solid tumors, and preparations to submit a New Drug Application for ALXN1840 for Wilson disease in early 2026. The company also completed a share repurchase of 550,229 shares from Tactic Pharma for $35 million, following a public offering, resulting in net proceeds of approximately $91.9 million before expenses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL1tBGxm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","LU2210149790.SGD","MNPR","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2583356005","title":"Press Release: Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2583356005","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583356005?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:00","pubTimestamp":1763038800,"startTime":"0","endTime":"0","summary":"WILMETTE, Ill., Nov. 13, 2025  -- Monopar Therapeutics Inc.  , a clinical--stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments.On September 14-15, 2025, the Company presented new data on the long-term neurological efficacy and safety of ALXN1840  at the 150th American Neurological Association  Annual Meeting. Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of Michigan delivered the poster and oral presentations. The new findings presented at ANA highlight the long-term neurological benefit of ALXN1840, and follow the European Association for the Study of the Liver  International Liver Congress presentation in May on the long-term hepatic and systemic safety and efficacy data. Together, these findings underscore the potential of ALXN1840 to favorably impact both neurological and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","R","BK4139","MNPR"],"gpt_icon":0},{"id":"2582870997","title":"Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2582870997","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582870997?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:55","pubTimestamp":1762786540,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jeet Mukherjee from BTIG maintained ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-potential-of-monopar-therapeutics-buy-rating-backed-by-alxn1840s-efficacy-and-safety-data-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-potential-of-monopar-therapeutics-buy-rating-backed-by-alxn1840s-efficacy-and-safety-data-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2582879873","title":"Leerink Partners Initiates Coverage on Monopar Therapeutics With Outperform Rating, $115 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879873","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879873?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:55","pubTimestamp":1762779358,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc (MNPR) has an average rating of Buy and mean price target of $113, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNPR"],"gpt_icon":0},{"id":"2582875487","title":"Piper Sandler Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875487","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875487?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:19","pubTimestamp":1762777145,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin maintained a Buy rating on Monopar Therapeutics Inc today and set a price target of $95.00. According to TipRanks,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2582787587","title":"Monopar Therapeutics Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2582787587","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582787587?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:09","pubTimestamp":1762776540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 07:09 ET (12:09 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"gpt_icon":0},{"id":"2582845578","title":"Monopar Therapeutics Inc : Chardan Capital Markets Raises Target Price to $100 From $85","url":"https://stock-news.laohu8.com/highlight/detail?id=2582845578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582845578?lang=en_us&edition=fundamental","pubTime":"2025-11-10 12:01","pubTimestamp":1762747299,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nFWN3WJ2CF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MNPR"],"gpt_icon":0},{"id":"2582180688","title":"Monopar presents new data, analyses from Phase 2 ALXN1840-WD-204 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2582180688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582180688?lang=en_us&edition=fundamental","pubTime":"2025-11-10 02:35","pubTimestamp":1762713312,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (MNPR) is presenting new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monopar-presents-new-data-analyses-from-phase-2-alxn1840-wd-204-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monopar-presents-new-data-analyses-from-phase-2-alxn1840-wd-204-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","MNPR","BK4229","BK4139","QCmain","WD","MHGmain"],"gpt_icon":0},{"id":"2582892414","title":"Monopar Therapeutics Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline","url":"https://stock-news.laohu8.com/highlight/detail?id=2582892414","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582892414?lang=en_us&edition=fundamental","pubTime":"2025-11-09 22:07","pubTimestamp":1762697260,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc. announced new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study evaluating tiomolybdate choline in patients with Wilson disease. The results, which were presented at the American Association for the Study of Liver Diseases  - The Liver Meeting 2025, demonstrated that treatment with ALXN1840 led to a rapid and sustained improvement in daily copper balance, primarily through increased fecal copper excretion. The mean daily copper balance among patients treated with ALXN1840 was significantly lower compared to their pre-treatment baseline. Additional nonclinical and clinical data supporting these findings from the ALXN1840-WD-204 study were also presented at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251109:nNDL217lBn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"gpt_icon":0},{"id":"2581317480","title":"BTIG Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581317480","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581317480?lang=en_us&edition=fundamental","pubTime":"2025-11-06 13:08","pubTimestamp":1762405704,"startTime":"0","endTime":"0","summary":"In a report released on November 4, Jeet Mukherjee from BTIG maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $104.00. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2581774544","title":"Cantor Fitzgerald Remains a Buy on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581774544","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581774544?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:46","pubTimestamp":1762357580,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-remains-a-buy-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-remains-a-buy-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR","BK4139"],"gpt_icon":0},{"id":"2580773012","title":"Monopar Therapeutics Inc  expected to post a loss of 43 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580773012","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580773012?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:13","pubTimestamp":1762265585,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc  expected to post a loss of43cents a share - Earnings Preview Monopar Therapeutics Inc MNPR.OQ MNPR.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG1WE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"gpt_icon":0},{"id":"2578622850","title":"Monopar Therapeutics’ Innovative Imaging Agent Study: Market Implications","url":"https://stock-news.laohu8.com/highlight/detail?id=2578622850","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578622850?lang=en_us&edition=fundamental","pubTime":"2025-10-28 02:10","pubTimestamp":1761588637,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc (($MNPR)) announced an update on their ongoing clinical study. Monopar Therapeutics Inc. is conducting an open-label pilot...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/monopar-therapeutics-innovative-imaging-agent-study-market-implications?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/monopar-therapeutics-innovative-imaging-agent-study-market-implications?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monopartx.com","stockEarnings":[{"period":"1week","weight":0.0134},{"period":"1month","weight":-0.0585},{"period":"3month","weight":0.641},{"period":"6month","weight":1.3335},{"period":"1year","weight":2.4217},{"period":"ytd","weight":2.5555}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.276364},{"month":2,"riseRate":0.333333,"avgChangeRate":0.12127},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.21291},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.030342},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.085228},{"month":6,"riseRate":0.666667,"avgChangeRate":0.04528},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.047687},{"month":8,"riseRate":0,"avgChangeRate":-0.159034},{"month":9,"riseRate":0.333333,"avgChangeRate":0.484161},{"month":10,"riseRate":0.5,"avgChangeRate":0.223985},{"month":11,"riseRate":0.666667,"avgChangeRate":0.047001},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.006269}],"exchange":"NASDAQ","name":"Monopar Therapeutics","nameEN":"Monopar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monopar Therapeutics,MNPR,Monopar Therapeutics股票,Monopar Therapeutics股票老虎,Monopar Therapeutics股票老虎国际,Monopar Therapeutics行情,Monopar Therapeutics股票行情,Monopar Therapeutics股价,Monopar Therapeutics股市,Monopar Therapeutics股票价格,Monopar Therapeutics股票交易,Monopar Therapeutics股票购买,Monopar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction